

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.7	45.6	47.8	47.0	46.4	47.6	48.4	42.6	54.9 ^g
1978-1980 ^b	48.1	46.2	50.1	48.1	46.4	49.9	51.1	47.1	56.7
1981-1983 ^b	50.9	50.5	51.2	51.1	50.7	51.4	49.9	49.4	50.4
1984-1986 ^b	51.8	50.2	53.5	52.1	50.8	53.7	47.1	44.5	50.4
1987-1989 ^b	51.1	47.9	55.1	51.6	48.4	55.4	46.4	41.7	52.1
1990-1992 ^b	50.9	46.8	56.0	51.7	47.7	56.7	42.1	38.2	47.6
1993-1995 ^b	52.7	49.0	57.6	53.5	50.0	57.9	42.0	36.0	53.5
1996-1998 ^b	59.0	57.2	61.2	59.7	57.8	61.8	54.0	52.5	56.3
1999-2001 ^b	64.1	61.6	67.1	65.1	63.0	67.6	55.8	49.0	63.8
2002-2008 ^b	70.6 ^f	69.5 ^f	71.9 ^f	71.8 ^f	71.0 ^f	72.7 ^f	62.8 ^f	58.7 ^f	67.4 ^f
5-Year Period Survival (Percent) ^{cd}									
2008	69.0	67.6	70.6	69.6	68.5	70.9	60.8	56.5	65.8
Stage Distribution (%) 2002-2008 ^{ce}									
All Stages									
Number of cases	89,792	48,135	41,657	75,733	40,620	35,113	7,103	3,834	3,269
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	27	30	28	27	29	27	25	30
Regional	15	15	16	15	15	16	15	14	16
Distant	48	50	46	49	51	46	50	54	47
Unstaged	8	8	9	8	8	9	8	7	8
5-Year Relative Survival (Percent), 2002-2008 ^c									
Age at Diagnosis:									
Ages <45	77.5	74.5	82.4	79.5	76.3	85.1	63.9	61.1	68.0
Ages 45-54	77.3	74.0	82.2	79.0	75.8	83.7	63.6	57.4	72.4
Ages 55-64	74.0	70.6	78.4	74.9	71.8	79.0	63.8	58.0	71.1
Ages 65-74	68.6	65.3	72.1	69.3	66.2	72.6	59.9	50.9	67.8
Ages 75+	52.3	51.5	53.0	53.0	52.4	53.5	47.1	45.3	47.8
Ages <65	76.1	72.9	80.6	77.4	74.4	81.9	63.9	59.2	70.4
Ages 65+	59.7	58.3	60.9	60.2	59.0	61.3	54.5	49.2	58.2
Stage ^e :									
All Stages	68.2	66.6	70.0	68.8	67.5	70.2	61.3	57.0	66.2
Localized	81.2	80.3	82.1	81.5	80.9	82.1	76.7	72.6	80.9
Regional	71.9	71.2	72.6	72.5	72.1	72.8	66.9	63.5	70.3
Distant	59.9	58.5	61.8	61.0	59.8	62.6	51.1	47.9	55.3
Unstaged	65.0	63.5	66.6	63.8	62.4	65.3	60.5	55.3	65.0

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2009.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2009.

^d Period survival provides a 2008 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2006-2008: 0-1 year survival), (2005-2007: 1-2 year survival), (2004-2006: 2-3 year survival), (2003-2005: 3-4 year survival), (2002-2004: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000.^f The difference between 1975-1977 and 2002-2008 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.